Cigna raised its annual profit forecast Thursday after beating quarterly earnings estimates on growth in its pharmacy and specialty drug businesses, lifting its 2026 adjusted profit forecast by 10 cents to at least $30.45 per share against analyst estimates of $30.41. The company earned $7.78 per share on an adjusted basis in the second quarter, beating estimates of $7.60, while total revenue rose 7% to $71.67 billion, ahead of the $70.34 billion analysts had projected. KeyToFinancialTrends notes that Cigna's forecast raise arrives as the direct payoff of a strategic retreat rather than organic growth alone: the company has spent the past year deliberately reducing its exposure to government-backed health insurance, exiting Medicare Advantage last year and announcing it will stop offering Affordable Care Act plans at the end of 2026, a pullback from lower-margin, higher-cost-volatility business lines that is now visibly showing up in improved results.
The specific business absorbing Cigna's strategic attention delivered the quarter's clearest growth story. Second-quarter adjusted revenue at the company's Evernorth Health Services unit, which includes pharmacy benefit management and specialty pharmacy, rose 6% to $61.47 billion, with growth partly driven by higher use of specialty drugs for complex conditions including cancer, multiple sclerosis, and rheumatoid arthritis. KeyToFinancialTrends treats that specialty-drug demand as a structurally durable growth driver rather than a temporary boost: conditions like cancer and multiple sclerosis require ongoing, often lifelong treatment regimens, meaning the pharmacy benefit volume Cigna is capturing through Evernorth reflects sustained patient need rather than a cyclical spike likely to reverse.
Not every metric moved in Cigna's favor, and the company's core insurance business showed some cost pressure worth isolating from the pharmacy-driven strength. The medical loss ratio, the percentage of premiums spent on medical care, came in at 84.5% for the quarter, up from 83.2% a year earlier and slightly above the 84.46% analysts had expected, with the company attributing part of that year-over-year increase to the prior-year quarter having benefited from higher risk-adjustment payments in its individual and family plans business. The editorial team frames that medical-loss-ratio uptick as a reminder that Cigna's improved forecast rests on a genuinely uneven foundation: the pharmacy and specialty drug businesses are carrying the quarter's growth story while the traditional insurance side absorbs rising medical costs, a combination that works as long as Evernorth's growth continues outpacing cost pressure elsewhere in the business.
Cigna's broader strategic pivot away from government programs and toward its employer-sponsored and pharmacy benefit businesses reflects a bet that predictability and scale in commercial healthcare will outperform the volatility that has characterized government-backed insurance lines industrywide in recent years. Key To Financial Trends closes on that pivot as the lens through which Thursday's raised forecast should be read: rather than simply beating a single quarter's estimates, Cigna is demonstrating that a multiyear strategic retreat from ACA and Medicare Advantage exposure, made specifically because of elevated and unpredictable medical costs in those programs, is now translating into the kind of earnings consistency that lets a health insurer confidently raise full-year guidance rather than merely defend it.
